VANCENASE AQ Drug Patent Profile
Which patents cover Vancenase Aq, and what generic alternatives are available?
Vancenase Aq is a drug marketed by Schering and is included in two NDAs.
The generic ingredient in VANCENASE AQ is beclomethasone dipropionate monohydrate. There is one drug master file entry for this compound. Additional details are available on the beclomethasone dipropionate monohydrate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VANCENASE AQ?
- What are the global sales for VANCENASE AQ?
- What is Average Wholesale Price for VANCENASE AQ?
Summary for VANCENASE AQ
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 63 |
| Clinical Trials: | 2 |
| Patent Applications: | 5,300 |
| DailyMed Link: | VANCENASE AQ at DailyMed |
Recent Clinical Trials for VANCENASE AQ
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Fred Hutchinson Cancer Research Center | Phase 2 |
| Merck Sharp & Dohme Corp. | Phase 3 |
US Patents and Regulatory Information for VANCENASE AQ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Schering | VANCENASE AQ | beclomethasone dipropionate monohydrate | SPRAY, METERED;NASAL | 019589-001 | Dec 23, 1987 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Schering | VANCENASE AQ | beclomethasone dipropionate monohydrate | SPRAY, METERED;NASAL | 020469-001 | Jun 26, 1996 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
